Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8787436 | Journal of Cancer Research and Practice | 2017 | 14 Pages |
Abstract
Brentuximab vedotin is a quite safe and effective targeted drug for patients with CD30+ anaplastic large cell lymphoma, but we still need to be careful some rare and severe adverse events after brentuximab vedotin treatment. Here we present a 32-year-old Asian male with CD30+ anaplastic large cell lymphoma who received brentuximab vedotin treatment and admitted to our ward 12 days later because of severe pancreatitis. Although intensive care had given, he still expired as a result of acute pancreatitis with multiple organs failure. Unintended targeting of BV to the pancreatic cells is a possible etiology of such acute pancreatitis. Severe epigastric pain in patients after Brentuximab vedotin may be a warning of severe pancreatitis and more intensive care should be considered.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Chi-Ching Chen, Su-Peng Yeh,